Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403

PURPOSE: The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-fr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Goldberg, Sarah B., Redman, Mary W., Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E., Horn, Leora, Chen, Everett H., Mashru, Sandeep H., Gettinger, Scott N., Melnick, Mary Ann, Herbst, Roy S., Baumgart, Megan A., Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768342/
https://ncbi.nlm.nih.gov/pubmed/33021871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01149
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados